Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA

[Image: see text] Oncogenic mutations in the KRAS gene are well-established drivers of cancer. While the recently developed KRAS(G12C) inhibitors offer a targeted KRAS therapy and have shown success in the clinic, KRAS(G12C) represents only 11% of all KRAS mutations. Current therapeutic approaches f...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ACS Pharmacol Transl Sci
Egile Nagusiak: Papke, Bjoern, Azam, Salma H., Feng, Anne Y., Gutierrez-Ford, Christina, Huggins, Hayden, Pallan, Pradeep S., Van Swearingen, Amanda E. D., Egli, Martin, Cox, Adrienne D., Der, Channing J., Pecot, Chad V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Chemical Society 2021
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8033609/
https://ncbi.nlm.nih.gov/pubmed/33860195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.0c00165
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak